	Printable version
	Version PDF

Efficiency of topical imiquimod 5% cream in the management of chronic radiation dermatitis with multiple neoplasias

European Journal of Dermatology. Volume 16, Number 1, 56-8, January-February 2006, Therapy

Summary

Author(s) : Michael M Sachse, Jutta Zimmermann, Friedrich A Bahmer , Department of Dermatology, (Skin Cancer Centre Charité), Charité University Hospital, Schumannstr. 20/21, 10117 Berlin, Germany, Department of Dermatology, Hospital Bremen-Mitte, Sankt-Jürgen-Straße 1, 28205 Bremen, Germany.

Summary : The immune response modifier imiquimod 5% cream (Aldara ^®) was locally applied to an extensive thoracic chronic radiation dermatitis for 2 weeks on a once daily basis. After moderate to severe irritative reactions with erythema and crusted erosions, areas cleared up within 4 weeks. The patient has now been in complete remission for 2 years

Keywords : chronic radiation dermatitis, immune response modifier, imiquimod, actinic keratoses, basal cell carcinoma, squamous cell carcinoma

Pictures

Figure 1 Chronic radiation dermatitis (CRD) before imiquimod-treatment (Jan. 1998).

Figure 2 CRD same patient during Imiquimod-treatment of the right side (Feb. 2002).

Figure 3 CRD, same patient, 10 months after Imiquimod-treatment (Oct. 2003).